Chinook Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
May 12, 2022 16:00 ET
|
Chinook Therapeutics, Inc.
SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics Announces Upcoming Data Presentations and Investor Conference Call at the 59th European Renal Association (ERA) Congress
May 02, 2022 10:25 ET
|
Chinook Therapeutics, Inc.
Data on atrasentan to be presented in an oral presentation from the IgA nephropathy (IgAN) patient cohort of the phase 2 AFFINITY basket trialUpdated data to be presented from Cohort 1 of Part 3 of...
Chinook Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
April 25, 2022 16:05 ET
|
Chinook Therapeutics, Inc.
SEATTLE, April 25, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics Announces Initiation of Phase 1 Healthy Volunteer Trial of CHK-336, a First-in-Class LDHA Inhibitor to Treat Hyperoxalurias
April 12, 2022 08:00 ET
|
Chinook Therapeutics, Inc.
SEATTLE, April 12, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
April 05, 2022 16:05 ET
|
Chinook Therapeutics, Inc.
SEATTLE, April 05, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics, IgA Nephropathy Foundation and Komodo Health Collaborate to Provide Nephrologists with Support and Information to Help Reduce Barriers to Diagnosis and Care
April 05, 2022 08:00 ET
|
Chinook Therapeutics, Inc.
SEATTLE, April 05, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), the IgA Nephropathy Foundation and Komodo Health today announced an outreach initiative leveraging data and...
Chinook Therapeutics Announces Appointment of Dr. Mahesh Krishnan to its Board of Directors
March 21, 2022 08:15 ET
|
Chinook Therapeutics, Inc.
SEATTLE, March 21, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
March 17, 2022 16:00 ET
|
Chinook Therapeutics, Inc.
SEATTLE, March 17, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics to Present at Oppenheimer’s 32nd Annual Healthcare Conference
March 08, 2022 16:05 ET
|
Chinook Therapeutics, Inc.
SEATTLE, March 08, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics Announces Upcoming Presentations at 4th Annual Chronic Kidney Disease Drug Development Summit
February 22, 2022 08:15 ET
|
Chinook Therapeutics, Inc.
SEATTLE, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...